HWP
KRYS icon

Highline Wealth Partners’s Krystal Biotech KRYS Stock Holding History

Highline Wealth Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$1.8K – 998
2025
Q1 		$1.8K Buy
+10
New +$1.68K ﹤0.01% 654

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Highline Wealth Partners's KRYS Position: Q2 2025 in Review

Highline Wealth Partners sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 10 shares — an estimated $1.8K sold.

Highline Wealth Partners first reported a position in KRYS in Q1 2025 and held it in 1 quarter. The position peaked at $1.8K in Q1 2025. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Highline Wealth Partners reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Highline Wealth Partners sold 10 Krystal Biotech shares in Q2 2025, an estimated $1.8K.
  • Highline Wealth Partners first reported a position in Krystal Biotech in Q1 2025 and held it in 1 quarter.
  • Highline Wealth Partners's Krystal Biotech position peaked at $1.8K in Q1 2025.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Highline Wealth Partners's 13F filing for Q2 2025, filed 16 Jul 2025.